Press release
Investigation for NASDAQ: SRPT Investors over potential Wrongdoing at Sarepta Therapeutics, Inc.
An investigation on behalf of current long term investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) shares.
Investors who are current long term investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: SRPT stocks follows a lawsuit filed against Sarepta Therapeutics, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: SRPT stocks, concerns whether certain Sarepta Therapeutics, Inc. directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges that the Defendants made false and/or misleading statements and/or failed to disclose that golodirsen posed significant safety risks to patients, that consequently, the NDA package for golodirsen's accelerated approval was unlikely to receive FDA approval, and that as a result, Sarepta's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation for NASDAQ: SRPT Investors over potential Wrongdoing at Sarepta Therapeutics, Inc. here
News-ID: 1933210 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Sarepta
Limb Girdle Muscular Dystrophy Pipeline 2025: MOA, ROA, and Clinical Trial Insig …
Limb Girdle Muscular Dystrophy pipeline constitutes 20+ key companies continuously working towards developing 25+ Limb Girdle Muscular Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Limb Girdle Muscular Dystrophy Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/limb-girdle-muscular-dystrophy-lgmd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Limb Girdle Muscular Dystrophy Market.
The Limb Girdle Muscular Dystrophy Pipeline report…
Arrowhead and Sarepta Forge $11.38 Billion Partnership to Advance Neuromuscular …
► Global Gene Therapy Market Poised for Robust Growth
The global gene therapy market is experiencing significant expansion, driven by advancements in genetic research and increasing prevalence of genetic disorders. According to Maximize Market Research, the market was valued at USD 10.03 billion in 2024 and is projected to reach USD 32.89 billion by 2032, growing at a compound annual growth rate (CAGR) of 16% during the forecast period.
► Competitive…
Duchenne Muscular Dystrophy Market Growth, Demand, And Segments to 2033 Sarepta, …
Duchenne Muscular Dystrophy (DMD) is a severe form of muscular dystrophy, characterized by progressive muscle degeneration and weakness, primarily affecting boys due to its X-linked inheritance. It is caused by mutations in the dystrophin gene, which leads to a deficiency of dystrophin, a protein essential for muscle cell stability. The condition typically presents in early childhood, with affected individuals showing difficulty walking, running, and climbing stairs by the age of…
Limb Girdle Muscular Dystrophy Clinical Trials Assessment 2024: FDA Approvals, D …
(Albany, USA) Limb Girdle Muscular Dystrophy pipeline constitutes 20+ key companies continuously working towards developing 25+ Limb Girdle Muscular Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Limb Girdle Muscular Dystrophy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Limb Girdle Muscular Dystrophy Market.
The Limb Girdle Muscular Dystrophy Pipeline…
Overview of Global Gene Therapy Market | Biogen, Gilead Sciences, Inc., Sarepta …
Astute Analytica, a leading provider of market research and analysis, released its highly anticipated Market Analysis Report on the Global Gene Therapy Market. This comprehensive report aims to equip businesses with invaluable insights and data, enabling them to make informed decisions and stay one step ahead of the competition.
Access the Comprehensive PDF Market Research Analysis Report Here: https://www.astuteanalytica.com/request-sample/gene-therapy-market
The Global Gene Therapy Market accounted for close to US$ 3.44 billion…
Overview of Global gene therapy market | Sarepta Therapeutics, Inc., Amgen Inc.
Astute Analytica, a leading provider of market research and analysis, released its highly anticipated Market Analysis Report on the global gene therapy market. This comprehensive report aims to equip businesses with invaluable insights and data, enabling them to make informed decisions and stay one step ahead of the competition.
The global gene therapy market accounted for close to US$ 3.44 billion by 2022 and is forecast to see growth at a…
